| Previous Close | N/A |
| Open | N/A |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | N/A - N/A |
| 52 Week Range | undefined - undefined |
| Volume | N/A |
| Avg. Volume | N/A |
| Market Cap | N/A |
| Beta | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga•11 months ago
Why Britain's NHS Is Great, Despite Its Dire Financial Situation
Britain’s National Health Service (NHS) recently turned 68 years old, and, in spite of its bleak financial situation, the Independent’s Indie 100 shared 11 reasons to celebrate the birthday of the oldest ...
- TheStreet.com•last year
Opko Is a Buying Opportunity After FDA's Approval of Kidney Drug
Banking on its Rayaldee treatment, this once-quiet pharmaceutical company has stepped up its investor profile with its first analyst day and a recent move to Nasdaq.
Motley Fool•last yearHow Risky Is Opko Health Inc. Stock?
A pending FDA decision, uncertainty about potential markets, and questionable acquisition prices add up to significant risk for Opko shareholders.